Antitumor chemotherapy in combined treatment of patients with cancer of the larynx and hypopharynx

Yu V. Belevich, E. L. Choinzonov, V. E. Goldberg, S. Yu Chizhevskaya, I. G. Frolova, V. I. Chernov, Zh A. Startseva, A. V. Goldberg, D. E. Kulbakin, N. O. Popova, V. V. Vysotskaya, E. I. Simolina, E. A. Dudnikova

Research output: Contribution to journalArticlepeer-review

Abstract

Preliminary results of the evaluation of the effectiveness of combined treatment of 116 patients with morphologically verified squamous cell carcinoma of the larynx and hypopharynx II-IV (T2-4N0-2M0) stages of the tumor process for the period from 2006 to 2017 are presented in the article. Patients of the study group (n=20) underwent 2 courses neoadjuvant chemotherapy according to the scheme: docetaxel + cisplatin, followed by radiotherapy in the mode of multifraction of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). Patients included in the comparison group (n=96) underwent 2 courses of neoadjuvant chemotherapy according to the scheme: paclitaxel + carboplatin, followed by radiotherapy in the mode of multifractionation of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). The overall effectiveness of the treatment in the study group was 90,3 ± 3,1% (complete regression - 49,4 ± 4,0%, partial regression - 40,9 ± 5,2%), in the comparison group - 81,3 ± 4,0% (complete regression - 34,4 ± 4,8%, partial regression - 46,9 ± 5,1%). Differences between groups are statistically significant (p = 0,001).

Original languageEnglish
Pages (from-to)607-611
Number of pages5
JournalVoprosy Onkologii
Volume64
Issue number5
Publication statusPublished - 2018
Externally publishedYes

Keywords

  • Cancer of the larynx and hypopharynx
  • Combined modality treatment
  • Multifraction radiation therapy
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antitumor chemotherapy in combined treatment of patients with cancer of the larynx and hypopharynx'. Together they form a unique fingerprint.

Cite this